-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Monopar Therapeutics quarterly/annual Operating Income (Loss) history and growth rate from 2016 to 2023.
- Monopar Therapeutics Operating Income (Loss) for the quarter ending September 30, 2024 was -$1.57M, a 23.8% increase year-over-year.
- Monopar Therapeutics Operating Income (Loss) for the twelve months ending September 30, 2024 was -$7M, a 28.8% increase year-over-year.
- Monopar Therapeutics annual Operating Income (Loss) for 2023 was -$8.83M, a 16.2% increase from 2022.
- Monopar Therapeutics annual Operating Income (Loss) for 2022 was -$10.5M, a 15.4% decline from 2021.
- Monopar Therapeutics annual Operating Income (Loss) for 2021 was -$9.13M, a 40.2% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)